Advertisement
Screener

PFIZER INC (PFE) EBITDA

PFIZER INC (PFE) EBITDA

  • 2026-06-28: Basis Reported; EBITDA (m); Operating income (m); Depreciation and amortization $1.62B.
  • 2026-03-29: Basis Reported; EBITDA (m); Operating income (m); Depreciation and amortization $1.61B.
  • 2025-09-28: Basis Reported; EBITDA (m); Operating income (m); Depreciation and amortization $1.66B.
  • 2025-06-29: Basis Reported; EBITDA (m); Operating income (m); Depreciation and amortization $1.63B.

Historical EBITDA

EBITDA 3 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2026-06-28Reported(m)(m)$1.62B(m)(m)$533.00M*$835.00M*$4.09B(m)$3.41B-$407.00M
2026-03-29Reported(m)(m)$1.61B(m)(m)$436.00M$2.62B$3.55B(m)$2.96B$461.00M
2025-09-28Reported(m)(m)$1.66B(m)(m)$602.00M*$4.60B*$4.17B(m)$3.19B-$216.00M
2025-06-29Reported(m)(m)$1.63B(m)(m)$618.00M*-$582.00M*$3.78B(m)$3.42B$141.00M
2025-03-30Reported(m)(m)$1.62B(m)(m)$564.00M$2.33B$2.85B(m)$3.03B-$189.00M
2024-09-29Reported(m)(m)$1.75B(m)(m)$651.00M*$6.71B*$5.26B(m)$3.24B$234.00M
2024-06-30Reported(m)(m)$1.73B(m)(m)$637.00M*-$1.78B*$3.30B(m)$3.72B-$134.00M
2024-03-31Reported(m)(m)$1.74B(m)(m)$704.00M$1.09B$3.38B(m)$3.50B$293.00M
2023-04-02Reported(m)(m)$1.49B(m)(m)$1.14B$1.21B$4.89B(m)$3.42B$715.00M
2013-03-31Reported(m)(m)$1.77B(m)(m)$202.00M$2.30B$2.26B(m)$3.22B$1.11B
2012-04-01Reported(m)(m)$2.22B(m)(m)$254.00M$2.77B$2.75B(m)$3.97B$711.00M
2011-04-03Reported(m)(m)$2.10B(m)(m)$250.00M$4.64B$3.69B(m)$4.50B$894.00M
2010-04-04Reported(m)(m)$2.05B(m)(m)$305.00M-$6.36B$4.20B(m)$4.40B$1.14B
2009-03-29Reported(m)(m)$1.01B(m)(m)$253.00M$3.15B$1.41B(m)$2.88B$1.07B

EBITDA 12 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2025-12-31Reported(m)(m)$6.59B(m)(m)$2.63B$11.70B$16.07B(m)$13.79B-$266.00M
2024-12-31Reported(m)(m)$7.01B(m)(m)$2.91B$12.74B$17.85B(m)$14.73B-$28.00M
2023-12-31Reported(m)(m)$6.29B$50.91B(m)$3.91B$8.70B$24.95B(m)$14.77B-$1.11B
2022-12-31Reported(m)(m)$5.06B$91.79B(m)$3.24B$29.27B$34.34B(m)$13.68B$3.33B
2021-12-31Reported(m)(m)$5.19B$73.64B(m)$2.71B$32.58B$30.82B(m)$12.70B$1.85B
2020-12-31Reported(m)(m)$4.68B$41.65B(m)$2.23B$14.40B$8.48B(m)$11.60B$370.00M
2019-12-31Reported(m)(m)$5.75B$40.91B(m)$2.05B$12.59B$8.05B(m)$12.73B$583.00M
2018-12-31Reported(m)(m)$6.38B$40.83B(m)$1.98B$15.83B$8.99B(m)$12.61B-$266.00M
2017-12-31Reported(m)(m)$6.27B$52.55B(m)$1.96B$16.80B$11.23B(m)$14.80B-$9.05B
2016-12-31Reported(m)(m)$5.76B$52.82B(m)$1.82B$16.19B$12.32B(m)$14.84B$1.12B
2015-12-31Reported(m)(m)$5.16B(m)(m)$1.40B$14.69B(m)(m)$14.81B$1.99B
2014-12-31Reported(m)(m)$5.54B(m)(m)$1.20B$17.08B(m)(m)$14.10B$3.12B
2013-12-31Reported(m)(m)$6.31B(m)(m)$1.21B$17.68B$9.59B(m)$14.36B$4.31B
2012-12-31Reported(m)(m)$7.39B(m)(m)$1.33B$16.75B$9.82B(m)$15.17B$2.22B
2011-12-31Reported(m)(m)$8.70B(m)(m)$1.66B$20.24B$12.50B(m)$17.58B$3.62B
2010-12-31Reported(m)(m)$8.40B(m)(m)$1.51B$11.45B$14.79B(m)$18.97B$1.15B
2009-12-31Reported(m)(m)$4.76B(m)(m)$1.21B$16.59B$8.46B(m)$14.75B$2.15B
2008-12-31Reported(m)(m)$5.09B(m)(m)$1.70B$18.24B$8.11B(m)$14.54B$1.65B
2007-12-31Reported(m)(m)$5.20B(m)(m)$1.88B$13.35B$11.24B(m)$15.63B$1.02B

Similar stocks

Stock NameCountryMarket CapPE Ratio
ABBOTT LABORATORIES (ABT)United States$176.045B28.47
VERTEX PHARMACEUTICALS INC / MA (VRTX)United States$132.481B28.56
BRISTOL MYERS SQUIBB CO (BMY)United States$125.637B12.67
REGENERON PHARMACEUTICALS, INC. (REGN)United States$74.751B21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Zoetis Inc. (ZTS)United States$29.045B11.38
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64